Abstract
A young male schizophrenic presented with neuroleptic malignant syndrome (NMS). Risperidone was the probable precipitating agent. Rigidity and elevated CPK levels poorly responded to bromocriptine, but showed good response to dantrolene. The role of specific treatment and the differential response of the symptom clusters are discussed.
Keywords: NMS, risperidone, dantrolene and bromocriptine
Full Text
The Full Text of this article is available as a PDF (121.4 KB).